Program

 

Each session will feature 10-minute presentations coupled with 5-minute Q&As and ending with 20-minute panel discussions. All times below are in US Eastern Time – to review times in your own time zone, please use the green buttons below.

A PDF version of the program is available for download from the right.

PROGRAM AT-A-GLANCE

See DAY 1 date/times in your time zone          See DAY 2 date/times in your time zone          See DAY 3 date/times in your time zone

 

Wednesday, October 7, 2020
SESSION IOcular and Emerging Protein Biomarkers of ADRD, Biomarkers for FTDCO-CHAIRS:
Robert Dean, MD, PhD, Robert A. Dean Consulting
Tetsuyuki Maruyama, PhD, KPY Consulting
10:00-10:05Welcome & Introductory NotesHoward Fillit, MD, Alzheimer's Drug Discovery Foundation
10:05-10:10Session OverviewCO-CHAIRS:
Robert Dean, MD, PhD, Robert A. Dean Consulting
Tetsuyuki Maruyama, PhD, KPY Consulting
10:10-10:25Delivering Novel Neuro-retinal Biomarkers for the Early Diagnosis of Alzheimer's DiseaseThomas MacGillivray, PhD, University of Edinburgh
10:25-10:40Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer's Disease: A Preliminary ReportEliav Shaked, MSc, RetiSpec
Catherine Bornbaum, PhD, MBA, RetiSpec
10:40-10:55Fully Automated Plasma Assays as Screening Tests for Alzheimer-related Amyloid Beta PathologyHenrik Zetterberg, MD, PhD, University of Gothenburg
10:55-11:10Plasma Abeta as a Predictor of Amyloid Positivity in Alzheimer's DiseaseStephen Zicha, PhD, Foundation for the National Institutes of Health
Wesley Horton, MS, Foundation for the National Institutes of Health
11:10-11:25Tau and p-tau as Alzheimer Biomarkers - Assays, Methodological Aspects and Clinical Performance Kaj Blennow, MD, PhD, University of Gothenburg
11:25-11:40TABLOOD: a Biomarker Panel for Direct Assessment in Blood of Alzheimer's Disease Pathophysiological HallmarksDouglas Galasko, MD, University of California San Diego
11:40-12:00QUESTIONS and DISCUSSIONRobert Dean, MD, PhD, Robert A. Dean Consulting
12:00-12:05BREAK
12:05-12:20Studies on the Plasma Contact System in Alzheimer's DiseaseSidney Strickland, PhD, The Rockefeller University 
Erin Norris, PhD, The Rockefeller University
12:20-12:35Novel Platform for On-Chip Detection of Neuronal Extracellular Vesicle-Bound Peripheral
Biomarkers for Alzheimer’s Disease and Other Dementias
Amber Murray, PhD, Biological Dynamics
12:35-12:50Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation before Clinical Onset of DementiaBlaine Roberts, PhD, Emory University
12:50-13:05Protein Misfolding Cyclic Amplification (PMCA) Clinical Test for Detection of Aggregates of Misfolded α-SynucleinRussell Lebovitz, MD, PhD, Amprion Inc.
13:05-13:20Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)Laura Mitic, PhD, Bluefield Project to Cure FTD
13:20-13:35Using Large Data Approaches to Diagnose and Drug DementiaJudith Steen, PhD, Boston Children's Hospital
13:35-13:55QUESTIONS and DISCUSSIONTetsuyuki Maruyama, PhD, KPY Consulting
13:55-14:00CLOSING REMARKSRobert Dean, MD, PhD, Robert A. Dean Consulting
Tetsuyuki Maruyama, PhD, KPY Consulting
Thursday, October 8, 2020
SESSION IIPart 1: Molecular Biomarkers of ADRDCHAIR: James Gallarda, PhD, Dx Consultancy
Part 2: Digital Biomarkers of ADRDCHAIR: Lampros Kourtis, PhD, Circadic.io
10:00-10:05Welcome & Introductory NotesJames Gallarda, PhD, Dx Consultancy
10:05-10:20Liquid Biopsy to Detect Cell Death in Alzheimer's DiseaseYuval Dor, PhD, Hebrew University
10:20-10:35Validation of a Rapid Non-invasive Diagnostic Test to Predict MCI and early Alzheimer's DiseaseHüseyin Firat, MD, PhD, Amoneta Diagnostics S.A.S.
10:35-10:50Blood-Based miRNA Diagnostics of Alzheimer's DiseaseBruno Steinkraus, PhD, Hummingbird Diagnostics GmbH
10:50-11:05Mitochondrial Epigenetics, a Tool for An Early AD DiagnosisMarta Barrachina, PhD, ADmit Therapeutics S.L.
11:05-11:20Plasma Cell-Free RNA as Alzheimer's Disease Non-invasive BiomarkerLaura Ibanez, PhD, Washington University
11:20-11:35Association between Plasma microRNA and other AD Markers in Cognitively Normal Study ParticipantsKira Sheinerman, PhD, MBA, Diamir Biosciences
11:35-11:50Aptamarker Diagnosis of Alzheimer’s Risk Factor in BloodGregory Penner, PhD, NeoNeuro
11:50-12:10QUESTIONS and DISCUSSIONJames Gallarda, PhD, Dx Consultancy
12:10-12:15BREAK
12:15-12:20Introduction to the session on Digital BiomarkersLampros Kourtis, PhD, Circadic.io
12:20-12:35Novel Virtual Reality Method to Distinguish Apathy from Depression in the Context of DementiaRamit Ravona-Springer, MD, Sheba Medical Center
12:35-12:50Digitally-enhanced Personalized Medicine: Accurate Selection of Subjective Cognitive Decline and Measuring Progression of Mild Cognitive ImpairmentCarolina Minguillón, PhD, Barcelonaβeta
12:50-13:05Smartphone-based Learning and Memory Assessment (LilaTM): Beta Application DevelopmentChris Edgar, PhD, Cogstate Ltd
13:05-13:20Alzheimer's Disease Digital Biomarker Discovery: Framingham Cognitive Aging and Dementia Study Rhoda Au, PhD, Boston University
13:20-13:35Detecting Cognitive Impairment and Measuring Cognitive Change: Responding to Modern ChallengesJennifer Rae Myers, PhD, Neurotrack
13:35-13:55QUESTIONS and DISCUSSIONLampros Kourtis, PhD, Circadic.io
13:55-14:00Closing Remarks Niranjan Bose, PhD, Gates Ventures
Friday, October 9, 2020
Session IIIDigital and Ocular BiomarkersCO-CHAIRS:
Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation
Eric Siemers, MD, Siemers Integration LLC
17:00-17:05Welcome & Introductory NotesNicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation
17:05-17:20Machine Learning Technologies for Advancing Digital Biomarkers for Alzheimer's DiseaseGuoliang Xing, DSc, The Chinese University of Hong Kong
17:20-17:35Threats to Digital Biomarkers and how Data Sharing Can HelpLarsson Omberg, PhD, Sage Bionetworks
17:35-17:50A Retinal Imaging Biomarker of Alzheimer's DiseasePeter Van Wijngaarden, MBBS, PhD, FRANZCO, Center for Eye Research Australia
17:50-18:05QUESTIONS & DISCUSSIONNicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation
Eric Siemers, MD, Siemers Integration LLC
18: 05-18:15CLOSING REMARKSHoward Fillit, MD, Alzheimer's Drug Discovery Foundation
Niranjan Bose, PhD, Gates Ventures

WELCOME NOTES

Wednesday, October 7, 2020
10:00 US Eastern Time

CONCLUDING REMARKS

Friday, October 9, 2020
18:05 US Eastern Time

Organizers/Hosts

Howard Fillit
Alzheimer’s Drug Discovery Foundation

Niranjan Bose
Gates Ventures

SESSION I

Ocular and Emerging Protein Biomarkers of ADRD, Biomarkers for FTD

This session will cover ocular approaches for the detection of Alzheimer’s disease and transition to the methods to measure the well studied and emerging biomarkers) of Alzheimer’s disease and conclude with notable biomarker efforts in the area of frontotemporal degeneration.

 

Wednesday, October 7, 2020

10:05 – 14:00 US Eastern Time

Robert Dean
Robert A. Dean Consulting

CO-CHAIR

Tetsuyuki Maruyama
KPY Consulting

CO-CHAIR

Thomas MacGillvray
University of Edinburgh

Delivering Novel Neuro-retinal Biomarkers for the Early Diagnosis of Alzheimer’s Disease

Eliav Shaked
RetiSpec

Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer’s Disease: A Preliminary Report

Catherine Bornbaum
RetiSpec

Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer’s Disease: A Preliminary Report

Henrik Zetterberg
Univ of Gothenburg

Fully Automated Plasma Assays as Screening Tests for Alzheimer-related Amyloid Beta Pathology

Stephen Zicha
Fdtn for the NIH

Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease

Wesley Horton
Found. for NIH

Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease

Kaj Blennow
Univ of Gothenburg

Tau and p-tau as Alzheimer Biomarkers – Assays, Methodological Aspects and Clinical Performance

Douglas Galasko
UCSD

TABLOOD: a Biomarker Panel for Direct Assessment in Blood of Alzheimer’s Disease Pathophysiological Hallmarks

Sydney Strickland
The Rockefeller Univ.

Studies on the Plasma Contact System in Alzheimer’s Disease

Erin Norris
The Rockefeller Univ.

Studies on the Plasma Contact System in Alzheimer’s Disease

Amber Murray
Biological Dynamics

Novel Platform for On-Chip Detection of Neuronal Extracellular Vesicle-Bound Peripheral Biomarkers for Alzheimer’s Disease and Other Dementias

Blaine Roberts
Emory University

Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation before Vlinical Onset of Dementia

Russell Lebovitz
Amprion

Role of Misfolded Synuclein in the Diagnosis and Characterization of Alzheimer’s and Atypical Dementias

Laura Mitic
Bluefield Project

Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)

Judith Steen
Boston Children’s Hospital

Using Large Data Approaches to Diagnose and Drug Dementia

SESSION II

Part 1: Molecular Biomarkers of ADRD

Part 2: Digital Biomarkers of ADRD

This session will cover the molecular approaches to expand our understanding of Alzheimer’s disease and will be followed by a session on how ubiquitous digital devices such as smart phone use can provide clues in the detection and monitoring of cognition.

 

Thursday, October 8, 2020

10:05 – 13:50 US Eastern Time

James Gallarda
Dx Consultancy

CO-CHAIR

Lampros Kourtis
Circadic.io

CO-CHAIR

Yuval Dor
Hebrew University

Liquid Biopsy to Detect Cell Death in Alzheimer’s Disease

Hüseyin Firat
Amoneta Dx

Validation of a Rapid Non-invasive Diagnostic Test to Predict MCI and early Alzheimer’s Disease

Bruno Steinkraus
Hummingbird Diagnostics

HBDx-AD: A Validated Blood-based microRNA Diagnostic Kit for Alzheimer’s Disease

Marta Barrachina
ADmit Therapeutics

Delivering Novel Neuro-retinal Biomarkers for the Early Diagnosis of Alzheimer’s Disease

Laura Ibanez
Washington Univ

Plasma Cell-Free RNA as Alzheimer’s Disease Non-invasive Biomarker

Kira Sheinerman
Diamir Biosciences

Circulating Brain-enriched microRNAs as Peripheral Biomarkers of Neurodegeneration

Gregory Penner
NeoNeuro

Aptamarker Diagnosis of Alzheimer’s Risk Factor in Blood

Ramit Ravona-Springer
Sheba Medical Center

Novel Virtual Reality Method to Distinguish Apathy from Depression in the Context of Dementia

Carolina Minguillon
Altoida

Novel Virtual Reality Method to Distinguish Apathy from Depression in the Context of Dementia

Chris Edgar
Cogstate

Smartphone-based Learning and Memory Assessment (LilaTM): Beta Application Development

Rhoda Au
Boston University

Novel Platform for On-chip Detection of Neuronal Extracellular Vesicles Biomarkers for Alzheimer’s Disease in Plasma

Jennifer Rae Myers
Neurotrack

Detecting Cognitive Impairment and Measuring Cognitive Change: Responding to Modern Challenges

SESSION III

Digital and Ocular Biomarkers

This session will be smorgasbord of non-invasive biomarker studies undertaken by our investigators in the Pacific Rim

 

Friday, October 9, 2020

17:00 – 18:15 US Eastern Time

Nicole Bjorklund
ADDF

CO-CHAIR

Eric Siemers
Siemers Integration

CO-CHAIR

Guoliang Xing
Chinese Univ HK

Machine Learning Technologies for Advancing Digital Biomarkers for Alzheimer’s Disease

Peter Van Wijngaarden
Ctr for Eye Res AU

A Retinal Imaging Biomarker of Alzheimer’s Disease

Larsson Omberg
Sage Bionetworks

Threats to Digital Biomarkers and how Data Sharing Can Help